A PEGylated fibrin patch for mesenchymal stem cell delivery

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Cardiovascular Research

Background:

• Mesenchymal stem cells (MSCs) show therapeutic potential for myocardial infarction but require effective delivery systems.
• Existing fibrin patches have limitations in mechanical properties and tailoring cell responses.
• Developing advanced biomaterials is crucial for successful stem cell transplantation.

Purpose of the Study:

• To develop and characterize a PEGylated fibrin patch for enhanced MSC delivery.
• To evaluate the impact of PEGylation on fibrin patch properties and MSC behavior.
• To assess the potential of the modified patch for myocardial infarction treatment.

Main Methods:

• Chemical PEGylation of fibrinogen (Fgn) to create secondary crosslinking.
• Verification of PEGylation using amine group quantification and SDS-PAGE.
• Assessment of patch properties, MSC viability, morphology, motility, and phenotypic changes (immunohistochemistry, RT-PCR).

Main Results:

• PEGylation was successfully achieved and verified.
• The PEGylated fibrin patch demonstrated comparable clotting and physical properties.
• Enhanced MSC viability and survival were observed within the PEGylated patch.
• Embedded MSCs exhibited phenotypic changes consistent with endothelial cells.

Conclusions:

• The developed PEGylated fibrin patch is a promising biomaterial for MSC delivery.
• PEGylation improves MSC viability and induces beneficial phenotypic changes.
• This enhanced delivery system holds potential for improving outcomes in myocardial infarction therapy.